5 Key Takeaways
-
1
Ligneous conjunctivitis is the most common manifestation of plasminogen deficiency type 1 (PLGD-1), affecting 81% of patients with ocular involvement.
-
2
The patient experienced multiple complications from PLGD-1, including recurrent lesions and organ dysfunction, before receiving a confirmed diagnosis at age 22.
-
3
RYPLAZIM, an FDA-approved treatment for PLGD-1, significantly improved the patient's symptoms and prevented recurrence of lesions after initiation at age 49.
-
4
Persistent conjunctivitis with lesions in the gingiva or other mucosal sites is highly suggestive of PLGD-1 and requires laboratory confirmation.
-
5
Effective communication among the patient's care team is crucial for accurate diagnosis and management of PLGD-1 to prevent serious complications.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.